The business has a range of around 22,000 special and special obtain products and regularly services 6,500 pharmacies and over 240 hospital accounts across the UK.
In 2009 LDC invested in the £32.5million management buy-out of Quantum Specials, one of the UK’s largest suppliers of tailored medicines to the pharmaceutical industry. In 2010, the name changed to Quantum Pharmaceutical.
Since the original investment, LDC supported a number of bolt-on acquisitions including that of Colonis, Protomed and Tomms to help broaden the business’ service offering. Revenues at the business more than doubled from £22million(2009) to £53.9million (2014) and employee numbers tripled from 100 (2009) to over 300 (2014).
On December 11 2014, Quantum Pharmaceutical commenced dealings on AIM following the successful pricing of the company’s IPO (26 November 2014). The business’ over £130million enterprise value on London’s AIM market will raise gross proceeds of £106.1million.
As part of the IPO process, LDC were keen to hold an ongoing stake in the business given the growth prospects from the newly licensed Colonis products and the desire of the management team to retain a material stake.
Following the IPO, LDC will retain an 8.2% equity stake, with directors and senior management of Quantum Pharma retaining approximately 8.5% of the issued share capital.
The flotation will support Quantum Pharma’s strategy to develop its product base and range across its five core business units in Quantum Pharmaceutical, U L Medicines, Colonis Pharma, Biodose and Quantum Aseptics.
LDC has been an extremely supportive partner over the past five years in providing the necessary investment to deliver a number of strategic acquisitions and provide transformative change to our facilities and product offering.Chief Executive Officer, Quantum Pharma plc